rs727504341
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 4P and 4B. PM1PP3_ModerateBS2
The NM_000432.4(MYL2):c.428C>T(p.Pro143Leu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000242 in 1,613,640 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_000432.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MYL2 | NM_000432.4 | c.428C>T | p.Pro143Leu | missense_variant | Exon 7 of 7 | ENST00000228841.15 | NP_000423.2 | |
MYL2 | NM_001406745.1 | c.386C>T | p.Pro129Leu | missense_variant | Exon 6 of 6 | NP_001393674.1 | ||
MYL2 | NM_001406916.1 | c.371C>T | p.Pro124Leu | missense_variant | Exon 7 of 7 | NP_001393845.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MYL2 | ENST00000228841.15 | c.428C>T | p.Pro143Leu | missense_variant | Exon 7 of 7 | 1 | NM_000432.4 | ENSP00000228841.8 | ||
MYL2 | ENST00000548438.1 | c.386C>T | p.Pro129Leu | missense_variant | Exon 6 of 6 | 3 | ENSP00000447154.1 | |||
MYL2 | ENST00000663220.1 | c.371C>T | p.Pro124Leu | missense_variant | Exon 7 of 7 | ENSP00000499568.1 |
Frequencies
GnomAD3 genomes AF: 0.0000132 AC: 2AN: 151950Hom.: 0 Cov.: 31
GnomAD3 exomes AF: 0.0000201 AC: 5AN: 248938Hom.: 0 AF XY: 0.0000223 AC XY: 3AN XY: 134734
GnomAD4 exome AF: 0.0000253 AC: 37AN: 1461690Hom.: 0 Cov.: 32 AF XY: 0.0000275 AC XY: 20AN XY: 727126
GnomAD4 genome AF: 0.0000132 AC: 2AN: 151950Hom.: 0 Cov.: 31 AF XY: 0.0000270 AC XY: 2AN XY: 74210
ClinVar
Submissions by phenotype
not specified Uncertain:2
The Pro143Leu variant in MYL2 has been identified by our laboratory in 1 African American teenager with HCM, who also carried a pathogenic variant in the MYBPC3 gene and had an earlier presentation than his mother, who only carried the MYBP C3 variant. This variant was absent from large population studies. Proline (Pro) at position 143 is highly conserved in evolution and the change to leucine (Leu ) was predicted to be pathogenic using a computational tool clinically validated by our laboratory. This tool's pathogenic prediction is estimated to be correct 94% of the time (Jordan 2011). Additional information is needed to fully assess the clinical significance of the Pro143Leu variant. -
- -
Hypertrophic cardiomyopathy 10 Uncertain:1
This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 143 of the MYL2 protein (p.Pro143Leu). This variant is present in population databases (rs727504341, gnomAD 0.006%). This missense change has been observed in individual(s) with hypertrophic cardiomyopathy (PMID: 27532257, 37652022). ClinVar contains an entry for this variant (Variation ID: 177824). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Hypertrophic cardiomyopathy 10;C5561937:Myopathy, myofibrillar, 12, infantile-onset, with cardiomyopathy Uncertain:1
- -
Hypertrophic cardiomyopathy Uncertain:1
This missense variant replaces proline with leucine at codon 143 of the MYL2 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). Splice site prediction tools suggest that this variant may not impact RNA splicing. To our knowledge, functional studies have not been performed for this variant. This variant has been reported in an individual affected with hypertrophic cardiomyopathy (PMID: 27532257). This variant has also been reported in an individual from a cohort of participants that were not pre-selected for a personal or family history of cardiovascular disorders (PMID: 22958901). This variant has been identified in 7/280276 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
Cardiovascular phenotype Uncertain:1
The p.P143L variant (also known as c.428C>T), located in coding exon 7 of the MYL2 gene, results from a C to T substitution at nucleotide position 428. The proline at codon 143 is replaced by leucine, an amino acid with similar properties. This alteration has been reported in the Framingham Heart Study cohort; however, clinical details were limited (Bick AG et al. Am J Hum Genet, 2012 Sep;91:513-9). Additionally, this alteration has also been detected in an individual who underwent genetic testing for hypertrophic cardiomyopathy, and in individual from a pediatric dilated cardiomyopathy cohort; however, clinical details were limited (Walsh R et al. Genet Med, 2017 02;19:192-203). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at